Search results
Found 10053 matches for
Researchers at the MRC Weatherall Institute of Molecular Medicine have recently discovered why a class of cancer drugs is beneficial only in a subset of patients. The results could pave the way for the future development of these drugs, known as PNP-inhibitors, as personalised medicines.
Anindita Roy
MRCPCH FRCPath PhD Anindita Roy - Professor of Paediatric Haematology
Michalina Mazurczyk
BSc. MSc. Michalina Mazurczyk - MRC WIMM Mass Cytometry Facility Manager
Andrew Armitage
M.Biochem, D.Phil Andrew Armitage - Senior Postdoctoral Scientist
Timothy Rostron
BSc; MSc Timothy Rostron - Sequencing and HLA Typing Laboratory Manager
Natalina Elliott
PhD-Cancer Biology, Vanderbilt University; BS-Recombinant Genetics & Chemistry, Western Kentucky University Natalina Elliott - Postdoctoral Researcher
Alain Townsend
FRS FRCP Alain Townsend - Emeritus Professor of Molecular Immunology